Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health (OPK) is positioned for growth due to the potential of its drug RAYALDEE and strategic partnerships, although overdependence on RAYALDEE remains a concern. The company is restructuring BioReference, advancing its 4Kscore test, and progressing a broad clinical-stage pipeline through its ModeX platform. Despite these positive factors, OPK faces clinical and regulatory risks, continued operating losses, and a reliance on RAYALDEE, leading to a negative estimate revision trend for 2026.
OPKO Health stock (US68375N1037): earnings update keeps focus on pipeline and Rayaldee outlook
OPKO Health recently released its quarterly earnings, providing updates on its pharmaceutical pipeline, including the Rayaldee franchise, and diagnostics operations. The company's business model integrates specialty pharmaceuticals with diagnostics, aiming to balance higher-margin drug sales with stable diagnostic income. Investors are looking at Rayaldee sales, diagnostic revenues, and pipeline progress as key catalysts, with the company navigating a competitive landscape and regulatory changes in the healthcare industry.
OPKO Health (OPK) price target increased by 11.18% to 3.86
This article reports that OPKO Health (OPK) has received an updated price target. The new price target of $3.86 represents an increase of 11.18% from the previous estimate.
OPKO Health stock (US68375N1037): Company updates keep the biotech name in focus
OPKO Health (OPK) remains a key focus for U.S. investors due to its diagnostics and biopharmaceutical businesses, with recent market coverage highlighting its small-cap profile and exposure to the healthcare sector. The company's diversified model, encompassing diagnostic testing services and pharmaceutical development, makes it sensitive to operating performance, market expectations, and specific company updates. For investors, OPKO Health offers exposure to both recurring service revenue and event-driven biotech catalysts, indicating that both fundamental business strength and broader market sentiment play a role in its stock performance.
Opko Health, Inc. - Common Stock (NQ: OPK)
This page provides news headlines and financial updates for Opko Health, Inc. (OPK), including details on recent earnings calls, quarterly reports, analyst ratings, and insider filings. Key information highlights past revenue misses, earnings beats, and stock performance shifts following financial announcements. The articles cover events from May 2026 back to May 2024, offering a comprehensive look at the company's financial activities and market reactions.
OPKO Health (OPK) price target increased by 11.18% to 3.86
This article reports that the price target for OPKO Health (OPK) has been increased by 11.18% to $3.86.
OPKO Health’s ModeX Therapeutics Will Present Data
OPKO Health’s ModeX Therapeutics will present preclinical data on its MDX3001 candidate at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting. The data demonstrates the in vivo generation of CAR-T cells and deep systemic B-cell depletion in animal models using its proprietary antibody-conjugated LNP/mRNA platform. This technology aims to simplify gene delivery for immune cells and offers a promising clinical modality for various diseases like autoimmunity and oncology.
OPKO Health stock (US68375N1037): Genomics leader with recent subsidiary activity
OPKO Health, through its subsidiary GeneDx, maintains a strong position in the genomics sector, specializing in genetic testing for rare disorders. Recent trading data shows GeneDx with a market capitalization over $1 billion and significant stock volatility, relevant for US investors tracking biotech firms on Nasdaq. The company’s integrated model and focus on personalized medicine aim to provide a competitive edge despite affiliate challenges.
OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
ModeX Therapeutics, an OPKO Health company, is set to present preclinical data at the ASGCT 2026 Annual Meeting. The data will highlight the in vivo generation of CAR-T cells and significant systemic B-cell depletion achieved with its MDX3001 candidate using its novel CD3xCD28 antibody-conjugated LNP/mRNA platform. This innovative approach simplifies treatment by enabling direct in vivo T-cell engineering and negates the need for pre-conditioning chemotherapy, offering potential in autoimmunity and oncology.
Spotlight On Promising Penny Stocks For May 2026
This article highlights promising penny stocks for May 2026, noting that despite an outdated term, they offer growth potential. It presents a list of top US penny stocks and provides detailed financial health analyses for Codexis (CDXS), OPKO Health (OPK), and Hyliion Holdings (HYLN), discussing their current financial situations, challenges, and future prospects. The report emphasizes the current market condition where the US market has seen significant growth over the past year.
Spotlight On Promising Penny Stocks For May 2026
This article identifies promising penny stocks for May 2026, highlighting companies with growth potential despite their lower price points. It features Codexis (CDXS), OPKO Health (OPK), and Hyliion Holdings (HYLN), detailing their financial health, operational revenue, market capitalization, and key challenges or opportunities. The piece emphasizes that while these companies present risks like unprofitability or volatility, they also show potential through innovation and strategic financial management.
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages
OPKO Health, Inc. (NASDAQ:OPK) has received a consensus "Hold" rating from six brokerages, with an average 12-month price target of $1.55. The company recently reported an EPS of ($0.07), matching estimates, but revenue of $124.2 million missed expectations and was down 17.1% year-over-year. Institutional investors currently own 64.63% of the stock.
OPKO Health (NasdaqGS:OPK) Stock Forecast & Analyst Predictions
OPKO Health (NasdaqGS:OPK) is forecast to grow earnings and revenue by 30.9% and 3.9% per annum respectively, although it is expected to remain unprofitable for the next three years. Analyst price targets have seen various adjustments, with a recent increase to US$3.76, while the stock has experienced a 17% decline over the past year. Insider transactions show significant buying activity from the Chairman & CEO, Phillip Frost, indicating confidence despite the company's financial risks and mixed analyst sentiment regarding revenue quality and future catalysts.
[ARS] OPKO HEALTH, INC. SEC Filing
This article announces an ARS SEC filing by OPKO HEALTH, INC. (OPK) on April 30, 2026. The filing indicates low impact and neutral sentiment. The article also provides recent news and other SEC filings related to OPKO Health, along with key stock data.
HC Wainwright Boosts Earnings Estimates for OPKO Health
HC Wainwright has increased its FY2026 earnings estimates for OPKO Health, forecasting a narrower loss of ($0.30) EPS, up from ($0.31). This adjustment follows OPKO's Q1 earnings which matched estimates at ($0.07) EPS, though revenue of $124.2 million fell short of consensus and was down 17.1% year-over-year. Despite mixed analyst sentiment and recent downgrades, strategic moves like the Nicoya RAYALDEE deal and BioReference Direct launch could provide future upside for the stock.
OPKO Health : Notice Annual Meeting of stockholders be held on Thursday, June 18, 2026.
OPKO Health Inc. announced that its Annual Meeting of Stockholders will be held on Thursday, June 18, 2026. The announcement was published on May 1, 2026, through Publicnow, and provides details regarding the company's contact information and regulatory filings. The company's General Counsel, Faibish Gabriel, signed the immediate report via MAGNA to the Israel Securities Authority.
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
OPKO Health has expanded its agreement with Nicoya Therapeutics to commercialize RAYALDEE® in Greater China, granting OPKO a 15% equity stake in Nicoya. This amendment reinforces Nicoya's commitment to the product and expands the range of its use, with regulatory approvals expected in China and related territories in 2027. The agreement aims to address the significant market opportunity in China, where over 20 million adults are affected by chronic kidney disease.
Kidney drug RAYALDEE targets China as OPKO takes 15% Nicoya stake
OPKO Health has amended its agreement with Nicoya Therapeutics, acquiring a 15% equity stake in Nicoya in exchange for a revised royalty and transfer-price schedule for RAYALDEE commercialization in Greater China. This deal expands RAYALDEE's market into a region with over 20 million adults suffering from stage 3 or 4 chronic kidney disease, with regulatory approvals anticipated in China and related territories by 2027. OPKO is also eligible to receive up to $115 million in milestone payments under the original agreement.
OPKO Health receives 15% stake in Nicoya for China drug rights
OPKO Health's subsidiary, EirGen Pharma Limited, has amended its agreement with Nicoya Therapeutics, resulting in OPKO receiving a 15% equity stake in Nicoya. This stake is in exchange for revised royalty and transfer price terms for the commercialization of RAYALDEE in Greater China. The deal, which could see OPKO receive up to $115 million in milestones, focuses on the significant growth opportunity presented by China's large chronic kidney disease patient population.
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
OPKO Health has expanded its agreement with Nicoya Therapeutics to strengthen the commercialization of RAYALDEE® in Greater China. The amended agreement grants OPKO a 15% equity interest in Nicoya and reinforces Nicoya’s commitment to launching RAYALDEE, with regulatory approvals expected in China and related territories in 2027. This collaboration aims to address the significant unmet need for treating secondary hyperparathyroidism in chronic kidney disease patients in the region.
Q1 Earnings Estimate for OPKO Health Issued By HC Wainwright
HC Wainwright has issued its Q1 2027 earnings per share (EPS) estimates for OPKO Health (NASDAQ:OPK), projecting ($0.07) EPS for the quarter and ($0.30) for the full year 2027, which is weaker than the consensus. OPKO Health recently reported Q1 2026 earnings of ($0.07) EPS, meeting estimates but with revenue of $124.20 million falling short of expectations and down 17.1% year-over-year. The company's stock currently holds an average "Hold" rating from analysts with an average target price of $1.55, and institutional investors have shown mixed activity in their holdings.
BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
BioReference Health LLC has launched BioReference Direct, a new digital platform providing consumers with direct access to high-quality laboratory testing. This platform aims to make healthcare more accessible and consumer-driven, offering a focused menu of tests for general wellness, women's health, men's health, and an at-home STI test through a collaboration with Abbott. BioReference Direct streamlines the process, allowing individuals to select tests, complete health intake, and receive results through a secure digital experience, sometimes even without an in-office healthcare provider visit.
OPKO Health Down Over 13%, On Pace for Largest Percent Decrease Since January 2024 -- Data Talk
OPKO Health (OPK) experienced a significant downturn, with its shares falling over 13% and putting the company on track for its largest single-day percentage decrease since January 2024. This notable drop indicates a challenging period for the company's stock performance.
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y
OPKO Health reported a Q1 2026 loss of 7 cents per share, matching Zacks Consensus Estimate, but revenues fell 25.7% year over year to $124.2 million, missing estimates. The revenue decline was primarily due to a smaller Diagnostics unit after asset divestitures, though this was partly offset by strong pharmaceutical product sales and improved cost structure. The company is advancing its ModeX pipeline and has an active share repurchase program.
H.C. Wainwright reiterates Opko Health stock rating on Q1 results
H.C. Wainwright maintained a Buy rating and $3.00 price target on Opko Health (NASDAQ:OPK) after its Q1 2026 earnings report. The company reported a 17.2% year-over-year revenue decline to $124.2 million, missing both analyst projections and its own guidance, primarily due to divestitures and a net loss of $54.8 million. Despite the revenue miss and anticipated sales decline for the year, the analyst's optimism aligns with a broader "Buy" consensus among Wall Street analysts, citing the company's strong short-term liquidity.
OPKO Health Q1 2026 Earnings Call: Complete Transcript
OPKO Health (NASDAQ: OPK) reported first-quarter 2026 revenue of $124.2 million, a decrease from Q1 2025, but with an improved operating loss. The company is advancing its Modex product development pipeline, including several clinical trials for oncology, immunology, and infectious diseases, and is engaged in collaborations with Regeneron and BARDA. OPKO's diagnostics business is streamlining operations to achieve breakeven by mid-year, focusing on regional clinical labs and the 4Kscore test, all supported by a strong cash position of $341 million.
OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ... By GuruFocus
OPKO Health Inc (OPK) reported its Q1 2026 earnings, detailing a decline in total revenue but an improvement in operating and net losses compared to the previous year. The company highlighted progress in its MODEX product pipeline and strong cash position while addressing challenges such as decreased BARDA funding and delays in planned activities. Discussions also covered updates on the 4K score test, growth expectations for the base business, and progress in various clinical trials and partnerships.
OPKO Health: Q1 Earnings Snapshot
OPKO Health Inc. (OPK) reported a first-quarter loss of $54.8 million, or 7 cents per share, meeting Wall Street expectations. However, the company's revenue of $124.2 million fell short of analyst forecasts. For the upcoming quarter and full year, OPKO Health provided revenue guidance of $127 million to $132 million and $530 million to $560 million, respectively.
OPKO Health (NASDAQ: OPK) Q1 2026 revenue falls as losses narrow and guidance held
OPKO Health reported Q1 2026 results with a decrease in total revenue to $124.2 million from $149.9 million a year earlier, primarily due to the sale of certain BioReference oncology assets. Despite the revenue fall, the company narrowed its operating loss to $51.0 million and net loss to $54.8 million, or $0.07 per share, demonstrating improved cost management. OPKO Health reiterated its full-year 2026 revenue guidance of $530–$560 million and provided Q2 2026 guidance between $127–$132 million, while continuing its stock repurchase program.
OPKO Health (NASDAQ:OPK) Announces Quarterly Earnings Results, Hits Estimates
OPKO Health (NASDAQ:OPK) announced its quarterly earnings, reporting an adjusted EPS of ($0.07), which met analyst estimates. However, the company's revenue of $124.2 million fell short of the $130.5 million consensus, and it remains unprofitable with negative net margins. Despite this, the stock saw a slight increase of 0.8% post-release, with institutional investors showing mixed activity but an overall "Hold" consensus rating from analysts.
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
OPKO Health (NASDAQ: OPK) reported its first-quarter 2026 financial results, showing a net loss of $54.8 million, or $0.07 per share, an improvement from the prior year. The company highlighted advancements in its pipeline, including the initiation of Phase 1 clinical trials for MDX2301 for COVID-19 prevention and MDX2003 for B-cell lymphoma, as well as an expanded partnership with Entera Bio for an oral PTH tablet. Total revenues for Q1 2026 were $124.2 million, a decrease primarily due to the sale of certain BioReference assets in 2025.
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
OPKO Health, Inc. reported its business highlights and financial results for the first quarter of 2026, ending March 31, 2026. Key highlights include the initiation of Phase 1 clinical trials for MDX2301 (COVID-19 prevention) and MDX2003 (B-cell lymphoma), as well as an expanded partnership with Entera Bio for an oral long-acting PTH tablet. Financially, the company saw consolidated total revenues of $124.2 million, an improved operating loss, and a net loss of $54.8 million for the quarter.
Here's Why You Should Hold OPK Stock in Your Portfolio for Now
OPKO Health (OPK) is positioned for growth due to its strategic transformation, increasing contributions from partnerships, and an advancing pipeline, particularly with RAYALDEE. However, the company faces a significant risk due to its overdependence on RAYALDEE, which is subject to market competition and pricing pressures. Despite this, analysts have stable estimates for the company's 2026 performance.
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
ModeX Therapeutics, an OPKO Health company, has dosed patients in a Phase 1 clinical trial for MDX2003, a novel tetraspecific T-cell engager for relapsed or refractory B-cell lymphoma. This antibody targets CD19 and CD20 on B-cells and CD3 and CD28 on T-cells, aiming to optimize tumor killing and prevent immune escape. The study will evaluate the safety, tolerability, pharmacokinetics, and immune activity of MDX2003 in adult patients with B-cell lymphoma.
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
ModeX Therapeutics, an OPKO Health company, has dosed patients in a Phase 1 clinical trial for MDX2003, a novel tetraspecific T-cell engager for relapsed or refractory B-cell lymphoma. MDX2003 targets CD19 and CD20 on B-cells and CD3 and CD28 on T-cells, aiming to optimize tumor killing and address immune escape. This study will assess the safety, tolerability, pharmacokinetic, and immune activity of the antibody in adult patients with B-cell lymphoma.
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
ModeX Therapeutics, an OPKO Health company, has initiated a Phase 1 clinical trial for MDX2003, a novel tetraspecific T-cell engager, to treat relapsed or refractory B-cell lymphoma. This first-in-class antibody targets CD19 and CD20 on B-cells and co-stimulatory T-cell activators CD3 and CD28, aiming to improve tumor killing and overcome immune escape. The study will evaluate the safety, tolerability, and activity of MDX2003 in adult patients with B-cell lymphoma, building on promising preclinical results.
OPKO to give 2026 guidance and business update after April 28 results
OPKO Health (NASDAQ: OPK) announced it will report its first quarter 2026 operating and financial results after market close on April 28, 2026. Management will host a conference call and live audio webcast on the same day at 4:30 p.m. Eastern time to discuss the results, provide a business update, and offer financial guidance. Investors can pre-register for the call or access it via dial-in numbers and a webcast.
A four-target antibody enters human testing in B-cell lymphoma
ModeX Therapeutics, an OPKO Health company, has started dosing patients in a Phase 1 clinical trial for MDX2003, a tetraspecific T-cell engager for relapsed or refractory B-cell lymphoma. This novel antibody targets four proteins (CD19, CD20, CD3, and CD28) aiming to improve tumor killing and overcome immune escape. The trial, NCT07249905, will evaluate MDX2003's safety, tolerability, pharmacokinetics, and immune activity in adult patients.
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
OPKO Health, Inc. (NASDAQ: OPK) announced it will report its first-quarter 2026 financial and operating results after the U.S. financial markets close on Tuesday, April 28, 2026. The company's senior management will host a conference call and live audio webcast on the same day at 4:30 p.m. Eastern time to discuss the results and provide financial guidance.
OPKO Health (OPK) to Release Earnings on Wednesday
OPKO Health (NASDAQ:OPK) is expected to release its Q1 2026 earnings after the market closes on Wednesday, April 29th, with analysts projecting a loss of ($0.07) per share on $130.5140 million in revenue. This follows a previous quarter where the biotechnology company beat consensus estimates, reporting ($0.04) EPS against an anticipated ($0.07) EPS. Institutional investors have recently increased their stakes in the company, though analysts currently rate the stock as a "Hold" with an average price target of $1.55.
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
OPKO Health's ModeX Therapeutics has initiated a clinical trial for MDX2003, a novel tetraspecific T-cell engager designed to treat relapsed or refractory B-cell lymphoma. This Phase 1 study will assess the safety, tolerability, pharmacokinetics, and immune activity of MDX2003, which targets CD19 and CD20 on B-cells, and CD3 and CD28 on T-cells to optimize tumor killing and address immune escape. The company anticipates defining dosing and treatment regimens for future efficacy trials based on this study's outcomes.
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
OPKO Health, Inc. (NASDAQ: OPK) announced it will report its first-quarter 2026 financial results after the U.S. financial markets close on Tuesday, April 28, 2026. Senior management will host a conference call and live audio webcast on the same day at 4:30 p.m. Eastern time to provide a business update, discuss results, and offer financial guidance. Participants are encouraged to pre-register for the call.
OPKO Health Inc stock (US68375N1037): Is its biotech pipeline strong enough to unlock new upside?
OPKO Health Inc. operates in the high-growth healthcare segments of diagnostics and therapeutics, leveraging a diversified model with laboratory services, pharmaceuticals, and biofabrication. The company's products, like the 4Kscore test and hGH-CTP, target large markets and offer competitive advantages, positioning it as a speculative growth play for investors. However, OPKO faces risks including reimbursement pressures, pipeline delays, and intense competition, which necessitate close monitoring of its execution and financial health.
OPKO Health, Inc. (OPK) Makes Progress on Game changing Covid-19 Treatment
OPKO Health, Inc. is advancing its COVID-19 prevention treatment, MDX2301, a tetravalent bispecific antibody with potential to neutralize all known SARS-CoV-2 variants. The company has completed a Phase 1 trial funded by federal grants, evaluating safety and tolerability. H.C. Wainwright maintains a "Buy" rating and a $3 price target, expecting positive pharmacokinetic and immunogenicity data by year-end, underscoring optimism for MDX2301's broad and durable protection capabilities.
9 Best Healthcare Penny Stocks to Buy According to Hedge Funds
This article identifies top healthcare penny stocks favored by hedge funds. It highlights OPKO Health, Inc. (NASDAQ:OPK) as one of the best picks, noting its significant upside potential and ongoing work on a promising COVID-19 prevention treatment. H.C. Wainwright reiterated a Buy rating and a $3 price target for OPK, based on its Phase 1 trial results for MDX2301 and its broad neutralization potential against SARS-CoV-2 variants.
OPKO Health (Nasdaq:OPK) - Stock Analysis
This Simply Wall St analysis provides a detailed look into OPKO Health (Nasdaq:OPK), highlighting its current market valuation, future growth prospects, and financial health. The report indicates the stock is currently trading below its estimated fair value, with key takeaways focusing on its diversified pipeline, strategic partnerships, and recent financial updates. Despite being unprofitable, the company has several encouraging developments and analyst insights on its diagnostic and pharmaceutical segments.
OPKO Health Receives 'Hold' Rating from Analysts
OPKO Health (NASDAQ:OPK) has received an average 'Hold' recommendation from analysts, with ratings ranging from 'Sell' to 'Strong Buy' and an average 12-month price target of $1.55. This mixed outlook reflects the challenges faced by the diversified healthcare company in its core business segments. Investors are advised to carefully evaluate the company's long-term potential amid ongoing uncertainties in the healthcare industry.
OPKO Health, Inc. (NASDAQ:OPK) Given Average Rating of "Hold" by Analysts
Analysts have given OPKO Health (NASDAQ:OPK) an average "Hold" rating, with a consensus 12-month price target of $1.55. Despite beating quarterly EPS and revenue estimates, the company reported a negative net margin and a 19.1% year-over-year revenue decline. Institutional ownership remains high at 64.63%, with major funds increasing their stakes in the biotechnology company.
OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
OPKO Health's ModeX Therapeutics has initiated a Phase 1 clinical trial for MDX2301, a multispecific antibody designed for the prevention of COVID-19. This tetravalent bispecific antibody aims to neutralize all known SARS-CoV-2 variants and is being evaluated for safety and tolerability in healthy volunteers and high-risk adults. The study, funded by the U.S. Department of Health and Human Services (HHS) ASPR/BARDA, represents a significant step in developing broad and durable protection against the evolving virus.
OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
OPKO Health's ModeX Therapeutics has begun a Phase 1 clinical trial for MDX2301, a tetravalent bispecific antibody designed to prevent COVID-19. This first-in-class multispecific antibody aims to neutralize all known variants of SARS-CoV-2 and will be evaluated for safety and tolerability in healthy volunteers and high-risk adults. The study, funded by HHS/ASPR/BARDA, represents a significant step in developing broader and more durable protection against evolving viral threats.
